Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: Cardiovascular Health Study

Atherosclerosis

Volumn 231, Issue 2, 2013, Pages 246-251

  Tehrani, David M ^a   Gardin, Julius M ^b   Yanez, David ^c   Hirsch, Calvin H ^d   Lloyd Jones, Donald M ^e   Stein, Phyllis K ^f   Wong, Nathan D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C reactive protein; Coronary heart disease; High density lipoprotein; Inflammation

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; TRIACYLGLYCEROL;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

C-REACTIVE PROTEIN; CORONARY HEART DISEASE; HIGH DENSITY LIPOPROTEIN; INFLAMMATION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AFRICAN AMERICANS; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CORONARY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84888095844     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.08.036     Document Type: Article

References (32)

1. Abbott R.D., Yano K., Hakim A.A., et al. Changes in total and high-density lipoprotein cholesterol over 10- and 20-year periods (the Honolulu Heart Program). Am J Cardiol 1998, 82:172-178.
2. Castelli W.P., Garrison R.J., Wilson P.W., Abbott R.D., Kalousdian S., Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAm Med Assoc 1986, 256:2835-2838.
3. Lagrand W.K., Visser C.A., Hermens W.T., et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. Circulation 1999, 100:96-102.
4. Ridker P.M. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 2004, 148:S19-S26.
5. Bassuk S.S., Rifai N., Ridker P.M. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004, 29:439-493.
6. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
7. Luc G., Bard J.M., Juhan-Vague I., et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol 2003, 23:1255-1261.
8. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. NEngl J Med 2000, 343:1148-1155.
9. Bilhorn K.R., Luo Y., Lee B.T., Wong N.D. High-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and cardiovascular disease in United States adults. Am J Cardiol 2012, 110:1464-1467.
10. Wong N.D., Malik S., Kashyap M.L. Preventive cardiology: a practical approach 2005, McGraw-Hill, New York, NY.
11. Fried L.P., Borhani N.O., Enright P., et al. The cardiovascular health study: design and rationale. Ann Epidemiol 1991, 1:263-276.
12. Cushman M., Cornell E.S., Howard P.R., Bovill E.G., Tracy R.P. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 1995, 41:264-270.
13. Macy E.M., Hayes T.E., Tracy R.P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997, 43:52-58.
14. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAm Med Assoc 2001, 285:2486-2497.
15. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511. Centers for Disease Control and Prevention; American Heart Association.
16. SAS Procedures guide 1995, SAS Institute, Cary, NC. 3rd ed.
17. Corsetti J.P., Gansevoort R.T., Sparks C.E., Dullaart R.P. Inflammation reduces HDL protection against primary cardiac risk. Eur J Clin Invest 2010, 40:483-489.
18. Ridker P.M., MacFadyne J.G., Wolfert R.L., Koenig W. Relationship of lipoprotein-associated phospholipase A(2) mass and activity with incident vascular events among primary prevention patients allocated to placebo or statin therapy: an analysis from the JUPITER trial. Clin Chem 2012, 58:877-886.
19. Tsimihodimos V., Karabina S.A., Tambaki A.P., et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 2002, 22:306-311.
20. Theilmeier G., De Geest B., Van Veldhoven P.P., et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J 2000, 14:2032-2039.
21. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707-714.
22. Ansell B.J., Navab M., Hama S., et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003, 108:2751-2756.
23. Briel M., Ferreira-Gonzalez I., You J.J., et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009, 338:b92.
24. de Haan W., de Vries-van der Weij J., van der Hoorn J.W., et al. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation 2008, 117:2515-2522.
25. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. NEngl J Med 2007, 357:2109-2122.
26. Boden W.E., Probstfield J.L., Anderson T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. NEngl J Med 2011, 365:2255-2267.
27. Joy T., Hegele R.A. Is raising HDL a futile strategy for atheroprotection?. Nat Rev Drug Discov 2008, 7:143-155.
28. Navab M., Hama S.Y., Cooke C.J., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. JLipid Res 2000, 41:1481-1494.
29. Ansell B.J., Fonarow G.C., Fogelman A.M. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 2007, 18:427-434.
30. Undurti A., Huang Y., Lupica J.A., Smith J.D., DiDonato J.A., Hazen S.L. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. JBiol Chem 2009, 284:30825-30835.
31. Navab M., Van Lenten B.J., Reddy S.T., Fogelman A.M. High-density lipoprotein and the dynamics of atherosclerotic lesions. Circulation 2001, 104:2386-2387.
32. Greenland P., Alpert J.S., Beller G.A., et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010, 122:2748-2764.